Federal HIV guidelines add Bixlenvo as a switch option, back statins for adults 40 to 75 and urge clinicians to challenge payer barriers to antiretroviral therapy (ART).
News|Articles|September 1, 2008
FDA Pipeline preview, September 2008
Recent FDA action (through September 2008) related to Immediate-release diclofenac capsules, tocilizumab, sugammadex, topical alprostadil cream, fospropofol, iloperidone, lacosamide, and vascular endothelial growth factor b.
Advertisement
Approvable designations
Recommended for approval
Nonapprovable designations
Advertisement
Related to this article
Sempre Health CEO Anurati Mathur says affordability dollars should reach patients on every fill, and reversed claims show plans when they don’t.
Based on her findings, Mathur shared members in a UPMC affordability program were more adherent to heart drugs, with fewer ER visits and no significant rise in total cost of care.
COPD patients who saw a care navigator had a 20% readmission rate vs. 35% for those who didn’t, in a quality improvement project at St. Joseph's Hospital in Tampa, Florida, according to research presented at CHEST 2026 meeting last week in Phoenix..
A standardized discharge checklist and care coordination cut 30-day COPD readmissions from 27.9% to 18.2%, according to research presented at CHEST 2026.
A Cencora analysis of 32 pre-approval products found more than 60% of payer engagement with PIE resources came more than 90 days after posting.
AMCP leaders say PBM reform, new drug pricing models and AI will shape this week’s Nexus meeting in San Diego.
Ty Gluckman, M.D., says missed lipid tests and clinical inertia, not prior authorization, are now the main barriers to reaching LDL goals.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Heart data in sleep study predicts atrial fibrillation, heart failure years in advance
2
AMCP Nexus 2026 preview: PBM reform rollout and drug pricing policy top the agenda
3
Christine Johnston on biosimilar interchangeability and PBM formularies
4
5 things you should know about intismeran, the Moderna-Merck cancer vaccine
5